Corrigendum: ELYPSE-7: A randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients. [Ann Oncol., 26, (2015) (1353-1362)] doi: 10.1093/annonc/mdv173;ELYPSE-7: A randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients

Annals of Oncology

Volumn 26, Issue 7, 2015, Pages 1353-1362

  Tredan O ^a,b,c,d   Menetrier Caux C ^b,c,d,e   Ray Coquard, Isabelle ^a,b,c,d   Garin, G ^a   Cropet, C ^a   Verronese E ^e   Bachelot, T ^a   Rebattu, P ^a   Heudel, P E ^a   Cassier, P ^a   Chabaud, S ^a   Croughs, T ^f   Dupont, P ^a   Cadore, A C ^a   Clapisson, G ^g   Delgado, A ^e   Bardin dit Courageot, C ^e   Rigal, C ^e   N'Kodia, A ^e   Gilles Afchain, L ^a   Morre, M ^g   Perol D ^a   Blay, J Y ^a,b,c,d   Caux, C ^b,c,d,e   more..

^a CENTRE LÉON BÉRARD   (France)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^e Leon Berard Cancer Center   (France)

^f Cytheris SA   (France)

^g Leon Berard Cancer Center ^*  (France)

Author keywords

Immune reconstitution; Interleukin 7; Lymphopenia; Metastatic breast cancer

Indexed keywords

CAPECITABINE; CYT 107; HEMATOLOGIC AGENT; PLACEBO; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ESTROGEN RECEPTOR; IL7 PROTEIN, HUMAN; INTERLEUKIN 7; PROGESTERONE RECEPTOR; RECOMBINANT PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CANCER FATIGUE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; FEVER; HAND FOOT SYNDROME; HUMAN; IMMUNOCOMPETENT CELL; INJECTION SITE REACTION; LEUKOPENIA; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MIDDLE AGED; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SKIN REDNESS; THROMBOCYTOPENIA; VOMITING; AGED; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; ENZYME IMMUNOASSAY; FOLLOW UP; LYMPH NODE METASTASIS; LYMPHOPENIA; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-7; LYMPHATIC METASTASIS; LYMPHOPENIA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECOMBINANT PROTEINS; SURVIVAL RATE;

EID: 84946728623     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx058     Document Type: Erratum

References (39)

1. Blay JY, Chauvin F, Le CA et al. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 1996; 14: 636-643.
2. Ceze N, Thibault G, Goujon G et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol 2011; 68: 1305-1313.
3. Gobert M, Treilleux I, Bendriss-Vermare N et al. Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. Cancer Res 2009; 69: 2000-2009.
4. Saroha S, Uzzo RG, Plimack ER et al. Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol 2013; 189: 454-461.
5. Blay JY, Le CA, Mermet C et al. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 1998; 92: 405-410.
6. Borg C, Ray-Coquard I, Philip I et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 2004; 101: 2675-2680.
7. Ray-Coquard I, Borg C, Bachelot T et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 2003; 88:181-186.
8. Manuel M, Tredan O, Bachelot T et al. Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. Oncoimmunology 2012; 1: 432-440.
9. Peron J, Cropet C, Tredan O et al. CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer 2013; 49: 1080-1089.
10. Ray-Coquard I, Ghesquiere H, Bachelot T et al. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 2001; 85: 816-822.
11. Tredan O, Manuel M, Clapisson G et al. Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. Eur J Cancer 2013; 49:1673-1682.
12. Fry TJ, Connick E, Falloon J et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001; 97: 2983-2990.
13. Fry TJ, Moniuszko M, Creekmore S et al. IL-7 therapy dramatically alters peripheral T-cell homeostasis in normal and SIV-infected nonhuman primates. Blood 2003; 101: 2294-2299.
14. Li B, VanRoey MJ, Jooss K. Recombinant IL-7 enhances the potency of GM-CSFsecreting tumor cell immunotherapy. Clin Immunol 2007; 123: 155-165.
15. Morre M, Beq S. Interleukin-7 and immune reconstitution in cancer patients: a new paradigm for dramatically increasing overall survival. Target Oncol 2012; 7: 55-68.
16. Huang M, Sharma S, Zhu LX et al. IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. J Clin Invest 2002; 109: 931-937.
17. Gou HF, Huang J, Shi HS et al. Chemo-immunotherapy with oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. PLoS One 2014; 9: e85789.
18. Sharma S, Batra RK, Yang SC et al. Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Hum Gene Ther 2003; 14: 1511-1524.
19. Beq S, Rozlan S, Gautier D et al. Injection of glycosylated recombinant simian IL-7 provokes rapid and massive T-cell homing in rhesus macaques. Blood 2009; 114:816-825.
20. Rosenberg SA, Sportes C, Ahmadzadeh M et al. IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ Tregulatory cells. J Immunother 2006; 29: 313-319.
21. Levy Y, Lacabaratz C, Weiss L et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009; 119: 997-1007.
22. Levy Y, Sereti I, Tambussi G et al. Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis 2012; 55: 291-300.
23. Sportes C, Hakim FT, Memon SA et al. Administration of rhIL-7 in humans increases in vivo TCR repertoire diversity by preferential expansion of naive T cell subsets. J Exp Med 2008; 205: 1701-1714.
24. Sportes C, Babb RR, Krumlauf MC et al. Phase I study of recombinant human interleukin-7 administration in subjects with refractory malignancy. Clin Cancer Res 2010; 16: 727-735.
25. Green S, Liu PY, O'Sullivan J. Factorial design considerations. J Clin Oncol 2002; 20: 3424-3430.
26. Perales MA, Goldberg JD, Yuan J et al. Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation. Blood 2012; 120: 4882-4891.
27. Mackall CL, Fry TJ, Gress RE. Harnessing the biology of IL-7 for therapeutic application. Nat Rev Immunol 2011; 11: 330-342.
28. Alderson MR, Tough TW, Ziegler SF et al. Interleukin 7 induces cytokine secretion and tumoricidal activity by human peripheral blood monocytes. J Exp Med 1991; 173: 923-930.
29. Menetrier-Caux C, Curiel T, Faget J et al. Targeting regulatory T cells. Target Oncol 2012; 7: 15-28.
30. Faget J, Bendriss-Vermare N, Gobert M et al. ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. Cancer Res 2012; 72:6130-6141.
31. Sisirak V, Faget J, Gobert M et al. Impaired IFN-alpha production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. Cancer Res 2012; 72: 5188-5197.
32. Younas M, Hue S, Lacabaratz C et al. IL-7 modulates in vitro and in vivo human memory T regulatory cell functions through the CD39/ATP axis. J Immunol 2013; 191: 3161-3168.
33. Simonetta F, Chiali A, Cordier C et al. Increased CD127 expression on activated FOXP3+CD4+ regulatory T cells. Eur J Immunol 2010; 40: 2528-2538.
34. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006; 107: 2409-2414.
35. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010; 33: 153-165.
36. Foureau DM, Amin A, White RL et al. Sequential immune monitoring in patients with melanoma and renal cell carcinoma treated with high-dose interleukin-2:immune patterns and correlation with outcome. Cancer Immunol Immunother 2014; 63: 1329-1340.
37. Thiebaut R, Drylewicz J, Prague M et al. Quantifying and predicting the effect of exogenous interleukin-7 on CD4+ T cells in HIV-1 infection. PLoS Comput Biol 2014; 10: e1003630.
38. Fyfe G, Fisher RI, Rosenberg SA et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13: 688-696.
39. Samlowski WE, Kondapaneni M, Tharkar S et al. Endothelial nitric oxide synthase is a key mediator of interleukin-2-induced hypotension and vascular leak syndrome. J Immunother 2011; 34: 419-427.